Clinical Trials Logo

Recurrent Childhood Visual Pathway Glioma clinical trials

View clinical trials related to Recurrent Childhood Visual Pathway Glioma.

Filter by:

NCT ID: NCT02780804 Recruiting - Clinical trials for Recurrent Childhood Visual Pathway Glioma

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: December 26, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

NCT ID: NCT02415153 Active, not recruiting - Clinical trials for Neurofibromatosis Type 1

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Start date: July 14, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of pomalidomide in treating younger patients with tumors of the brain or spine (central nervous system) that have come back or are continuing to grow. Pomalidomide may interfere with the ability of tumor cells to grow and spread and may also stimulate the immune system to kill tumor cells.

NCT ID: NCT02194452 Withdrawn - Adult Glioblastoma Clinical Trials

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Start date: September 2013
Phase: N/A
Study type: Interventional

This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT imaging, may help find and diagnose brain tumors.

NCT ID: NCT02175745 Terminated - Adult Glioblastoma Clinical Trials

18F FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly Diagnosed or Recurrent Gliomas

Start date: December 2014
Phase: N/A
Study type: Interventional

This clinical trial compares fluorine F 18 fluorodopa (18F FDOPA) positron emission tomography (PET) with standard magnetic resonance imaging (MRI) in measuring tumors in patients with glioma that is newly diagnosed or recurrent (has returned). 18F FDOPA is a radioactive drug that binds to tumor cells and is captured in images by PET. Computed tomography (CT) and MRI are used with PET to describe information regarding the function, location, and size of the tumor. PET/CT or PET/MRI may be more accurate than standard MRI in helping doctors find and measure brain tumors.

NCT ID: NCT01553149 Active, not recruiting - Clinical trials for Neurofibromatosis Type 1

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Start date: March 19, 2012
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment (refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas.

NCT ID: NCT01089101 Recruiting - Glioma Clinical Trials

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Start date: April 19, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01088763 Terminated - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00994500 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Start date: August 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00929903 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Start date: June 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00919750 Recruiting - Clinical trials for Recurrent Childhood Medulloblastoma

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Start date: March 2005
Phase: N/A
Study type: Observational

The purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory. Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future.